Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
McKinsey
Fuji
Express Scripts
Healthtrust
AstraZeneca

Generated: March 26, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MALARONE PEDIATRIC

« Back to Dashboard

Clinical Trials for Malarone Pediatric

Trial ID Title Status Sponsor Phase Summary
NCT00421473 Drug Interaction Study Between Atovaquone and Antiretroviral Agents in HIV-1 Infected Patients Completed Radboud University Phase 4 Malarone® (atovaquone/proguanil) is frequently used in malaria prophylaxis. Unfortunately, there are indications that certain anti-HIV agents may decrease atovaquone plasma levels by induction of atovaquone metabolism. For travelling HIV patients, the clinical consequences of these possible drug drug interactions are serious, since a diminished exposure to the anti-malarial drug will result in suboptimal prophylaxis of malaria and potential development of drug resistant strains of Plasmodium falciparum. The purpose of this study is to find out if HIV patients using HAART regimes with either lopinavir/ritonavir, atazanavir/ritonavir or efavirenz have lower atovaquone plasma levels than healthy volunteers after a single dose of atovaquone/proguanil.
NCT00444106 Evaluation of Potential Effect of Artemether - Lumefantrine and Malaria Drugs on Auditory Function Completed Novartis Phase 4 To evaluate the potential effects of artemether- lumefantrine on the auditory function
NCT00984256 Weekly Dosing of Malarone ® for Prevention of Malaria Completed U.S. Army Medical Research and Materiel Command Phase 2 The purpose of this study is to determine whether Malarone ®, which is a drug approved to prevent malaria when taken daily, will still effectively prevent malaria if taken weekly.
NCT01150344 Evaluation of the Riamet® Versus Malarone® in the Treatment of Uncomplicated Malaria Completed Assistance Publique - Hôpitaux de Paris Phase 4 Riamet® or Malarone® are both recommended as the first line treatment for uncomplicated malaria in France, according to the French consensus Conference revised in 2007 on the treatment of imported malaria. The aim of the study is to compare both tolerance and efficacy of Malarone® and Riamet® in the treatment of uncomplicated imported malaria and to determine clinical and parasitological predictive factors associated with a less effectiveness. It's a multicentric, randomised study in adults with uncomplicated malaria. Treatment will be administered for 3 days, and patients will be followed for 28 days, to evaluate the therapeutic evolution. 640 patients will be included among 15 centres.
NCT01479361 Antiretroviral Drug Interaction Study in Volunteers With HIV Completed National Institutes of Health Clinical Center (CC) Phase 1 Background: - People who are infected with the human immunodeficiency virus (HIV) are at risk of getting certain diseases. Two of these diseases are a type of pneumonia known as PCP and a brain infection called toxoplasmosis. Most people with HIV take antiretroviral (ARV) drugs to treat HIV and lower the risk of infections. However, some ARV drugs may make other drugs used to treat PCP and toxoplasmosis less effective. Researchers want to test specific ARV drugs to see if they affect atovaquone, a drug used to treat PCP and toxoplasmosis. Objectives: - To see if ARV drugs atazanavir-ritonavir or efavirenz lower the blood levels of atovaquone. Eligibility: - Individuals between 18 and 70 years of age who have HIV. - Participants must be taking efavirenz or atazanavir-ritonavir, or not taking any ARV drugs. Design: - Participants will be screened with a physical exam and medical history. They will also have blood and urine tests. - This study has a screening visit and five study visits. Two of the study visits will last about 12 hours; the other three visits will last about 1 hour each. - Participants will receive either a low dose or high dose of atovaquone to take for 14 days. They will record doses and any symptoms on a diary card at home. - After 14 days, participants will have a 12-hour visit to provide blood samples. There will be a wash-out period with no doses for up to 6 weeks. - After the wash-out period, participants will switch dose levels to either the high or low dose. - After 14 days, participants will have a 12-hour visit to provide blood samples.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Malarone Pediatric

Condition Name

Condition Name for Malarone Pediatric
Intervention Trials
Malaria 11
Malaria,Falciparum 2
Controlled Human Malaria Infection 2
Plasmodium Falciparum Infection 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Malarone Pediatric
Intervention Trials
Malaria 13
Malaria, Falciparum 3
Infection 2
Communicable Diseases 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Malarone Pediatric

Trials by Country

Trials by Country for Malarone Pediatric
Location Trials
Netherlands 8
United States 7
Colombia 1
Germany 1
France 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Malarone Pediatric
Location Trials
Maryland 4
Washington 2
New York 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Malarone Pediatric

Clinical Trial Phase

Clinical Trial Phase for Malarone Pediatric
Clinical Trial Phase Trials
Phase 4 4
Phase 2 2
Phase 1/Phase 2 1
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Malarone Pediatric
Clinical Trial Phase Trials
Completed 9
Recruiting 5
Not yet recruiting 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Malarone Pediatric

Sponsor Name

Sponsor Name for Malarone Pediatric
Sponsor Trials
Radboud University 6
The PATH Malaria Vaccine Initiative (MVI) 3
National Institute of Allergy and Infectious Diseases (NIAID) 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Malarone Pediatric
Sponsor Trials
Other 20
U.S. Fed 3
NIH 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Fuji
Farmers Insurance
Julphar
Moodys
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.